10.02.24 -- Sanofi, Sanctions, And Supply-Chain Challenges

Solid dose formulations are one of the most established dosage forms in pharmaceuticals. However, there are many challenges in their design, such as API stability, release kinetics or bioavailability limitations. With our comprehensive range of functional and particle-engineered Parteck® excipients, we’re here to meet your needs and help you ensure optimal performance in your formulation development and manufacturing. Learn more about our functional excipients

Antibody-drug conjugates usually deliver one payload type, which can overlook cancer’s complexity. A single ADC delivering two separate payloads could be the answer.

Chief Editor Louis Garguilo kicks off this virtual event by highlighting key questions to ask about the strategic direction of drug development and manufacturing outsourcing.

Drugs have become more lipophilic and complex in structure over time. Innovative strategies are needed to improve bioavailability of these new drugs.

Alternative solvent approaches could reduce volumes of less toxic solvents, significantly improving the environmental and human health impacts of new drugs.

See how Zydis ODT compares to standard oral tablets, how the same molecule can produce different outcomes when utilizing Zydis ODT, and findings from over 20 studies.

Review key trends and challenges in the CDMO industry and the tools helping to meet the demand for pediatric formulations and taste-masking solutions.

A pharma company sought a CMO partner with commercial manufacturing capabilities and expertise as well as exemplary quality systems to find a cost-effective process to produce the API for a new drug.

Join the next Outsourced Pharma Live as our panel explores the critical considerations and best practices for selecting and managing CDMOs in the development of novel therapies, including advanced therapy medicinal products like cell and gene therapies. Industry experts will share insights on evaluating CDMO capabilities, ensuring quality and compliance, and fostering effective partnerships to accelerate innovation while mitigating risks.

With ample available capacity, we provide the efficiency of five bottling lines with quick changeovers, online validated fill accuracy, and the flexibility to accommodate small lots to commercial runs for tablets, capsules, and powders.

We specialize in high-potency softgels and liquids and have deep experience producing prescription drugs for classifications including oncology, dermatology, the central nervous system and immunity.